AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.

RecruitingPhase 3Ages 18 Years - anyAllCentral Hospital, Nancy, France
💬

In plain words

What the trial is, and whether it could suit you

Long term prognosis of cardiogenic shock is related to the resolution of haemodynamic failure, associated visceral failure and the recovery of an adequate myocardial function. In the immediate aftermath of cardiogenic shock, after catecholamines weaning, there are no recommendations on cardiovascular treatments that would improve this long term prognosis. Indeed, the standard cardiovascular treatments such as inhibitors of the renin-angiotensin and aldosterone system and beta-blockers have hypotensive and negative inotropic effects and may worsen the renal function. In practice, given their side effects, they are not prescribed in the immediate aftermath of cardiogenic shock. Sodium-glucose co-transporter 2 (iSGLT2) inhibitors are now an integral part of the drug management of chronic heart failure and the EMPULSE-HF trial has just demonstrated a benefit in acute heart failure (PMID: 35

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Adult patients hospitalized in critical cardiac unit care or Intensive care unit for a cardiogenic shock * "Who must have been or is on catecholamines for at least 12 hours for the treatment of cardiogenic shock. * Patients who are able to take oral tablets Exclusion Criteria: * GFR\< 20 ml/min/1.73m2. * Chronic dialysis. * Patient on SGLT2 inhibitors prior to admission to ICU or CCU. * Known allergy to SGLT2 inhibitors or to any of its excipients (in particular, patients with hereditary disorders of galactose intolerance, total lactase deficiency or glucose or galactose malabsorption syndrome) * Patients on lithium. * Patient in shock for another cause or moribund (SAPS2\> 90). * Specific cardiogenic shock context: 1. cardiac transplant patient or on transplant list. 2. peripartum, adrenergic, valvular, non ischemic, post embolic heart disease. 3. related to cardiotropic drug intoxication. 4. Secondary to a cardiac arrest for which the patient remains comatose prior to inclusion. * Women of childbearing age without effective contraception. * Person referred to in Articles 10, 31, 32, 33 and 34 of EU Regulation 536/2014 (Pregnant woman, parturient or breastfeeding mother, Minor (not emancipated), Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice))
💊

What it tests

  • Empagliflozin 10 MG
📍

Where

8 sites
CHR Metz - Thionville
Ars-Laquenexy, France
CHU de Besançon
Besançon, France
CHU de Dijon Bourgogne
Dijon, France
CHU Lille
Lille, France
CHU Reims
Reims, France
Hôpitaux Universitaires de Strasbourg
Strasbourg, France
CHRU de NANCY - réanimation médicale
Vandœuvre-lès-Nancy, France
Chru Nancy - Usic
Vandœuvre-lès-Nancy, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy